These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10222840)

  • 1. [Carbohydrate antigens CA 19-9, CA 242, CA 50 in liver diseases].
    Nowak J; Jakubowska D; Wiczkowski A; Sprzaczkowska K; Stechły T; Zmudziński W; Grzesik P; Walas R; Jarzab B
    Wiad Lek; 1998; 51(11-12):484-91. PubMed ID: 10222840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H; Kaya M; Cengiz A
    Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How does liver dysfunction influence serum CA 19-9 in pancreatic cancer?
    Basso D; Fabris C; Del Favero G; Piccoli A; Angonese C; Pasquali C; Castoro C; Plebani M; Leandro G; Burlina A
    Ital J Gastroenterol; 1990 Feb; 22(1):1-6. PubMed ID: 2131920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases].
    Czakó L; Takács T; Babarczy E; Dux L; Lonovics J
    Orv Hetil; 1997 Nov; 138(47):2981-5. PubMed ID: 9432648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the clinical usefulness of CA 19-9 and CA 50 in the diagnosis and monitoring of gastrointestinal cancers.
    Kokociñska D; Jarzab B; Król R; Ziaja K; Szejbak K; Kuśmierski S
    J Environ Pathol Toxicol Oncol; 1996; 15(2-4):283-7. PubMed ID: 9216823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of CA 50 in nonmalignant liver diseases: a clinical and biochemical study.
    Collazos J; Genolla J; Ruibal A
    Am J Gastroenterol; 1993 Mar; 88(3):409-12. PubMed ID: 8438849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma.
    Hsu PI; Chow NH; Lai KH; Yang HB; Chan SH; Lin XZ; Cheng JS; Huang JS; Ger LP; Huang SM; Yen MY; Yang YF
    Anticancer Res; 1997; 17(4A):2803-9. PubMed ID: 9252719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of CA 242 and CA 19-9 serum tumor markers in colorectal cancer patients. A longitudinal evaluation.
    Spila A; Ferroni P; Cosimelli M; D'Alessandro R; Abbolito MR; Mariotti S; Aloe S; Carone MD; Graziano F; Tedesco M; Martini F; Mancini R; Stigliano V; Roselli M; Guadagni F
    Anticancer Res; 2001; 21(2B):1263-70. PubMed ID: 11396197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
    Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
    Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
    Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
    Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Carbohydrate antigen (CA-19-9) in the blood serum of patients with benign and malignant liver diseases].
    Ametov AS; Kasatkin IuN; Mit'kov VV; Gur'eva IV
    Med Radiol (Mosk); 1985 Mar; 30(3):39-41. PubMed ID: 3856723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum tumor markers in chronic liver disease.
    Kadayifci A; Simsek H; Savas MC; Toppare M
    Neoplasma; 1996; 43(1):17-21. PubMed ID: 8843954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer.
    Sato T; Nishimura G; Nonomura A; Miwa K; Miyazaki I
    Hepatogastroenterology; 1999; 46(26):914-9. PubMed ID: 10370638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normal interleukin-10 serum level opposed to high serum levels of carbohydrate antigen 19-9 and cancer antigens 125 and 50 in a case of true splenic cyst.
    Lieto E; Castellano P; Ferraraccio F; Orditura M; De Vita F; Romano C; Pignatelli C; Galizia G
    Arch Med Res; 2003; 34(2):145-8. PubMed ID: 12700012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnostic value of serum CA 19-9 determination in digestive tract cancer].
    Chen SB
    Zhonghua Zhong Liu Za Zhi; 1990 Jan; 12(1):58-60. PubMed ID: 2364873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer antigen 125 in patients with chronic liver disease.
    Devarbhavi H; Kaese D; Williams AW; Rakela J; Klee GG; Kamath PS
    Mayo Clin Proc; 2002 Jun; 77(6):538-41. PubMed ID: 12059123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serum determination of CA 19-9 in patients with digestive cancers and its diagnostic evaluation].
    Arakawa Y; Kobayashi H; Ozaki T; Ariga H; Matsuo Y; Honda T; Arai T; Kurosu Y; Morita K; Konuma H
    Gan To Kagaku Ryoho; 1984 Apr; 11(4):917-25. PubMed ID: 6586110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
    Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C
    Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of tissue polypeptide specific antigen as a marker in liver diseases.
    Cetin T; Oğuz A; Algan P; Yildirim IS
    Turk J Gastroenterol; 2003 Sep; 14(3):177-80. PubMed ID: 14655061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum leptin levels in patients with nonalcoholic chronic liver disease.
    Nakamuta M; Tada S; Uchimura K; Enjoji M; Kinukawa N; Iwamoto H; Sugimoto R; Shimada M; Ohashi M; Sugimachi K; Nawata H
    Hepatogastroenterology; 2001; 48(38):527-32. PubMed ID: 11379347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.